Landmark analysis: overall survival by major cytogenetic response status at 3 months.

Of 83 patients with an evaluation of cytogenetic response at 3 months after start of therapy, 20 (24%) had a major cytogenetic response at that time, and none of these 20 patients had died at the time of analysis. Of the 63 evaluated patients without major cytogenetic response after 3 months, 14 (22%) had died.